SCHEMBL30273141

SCHEMBL30273141

O=c1[nH]c2cc(CCl)ccc2n2cccc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 17/20 0.66
TP53 P04637 1/20 0.62
CDC7 O00311 2/20 0.60
PLK4 O00444 2/20 0.60
MAPK13 O15264 2/20 0.60
PDPK1 O15530 2/20 0.60
DYRK3 O43781 2/20 0.60
ERBB2 P04626 2/20 0.60
PRKCG P05129 2/20 0.60
ROS1 P08922 2/20 0.60
KIT P10721 2/20 0.60
SRC P12931 2/20 0.60
PHKG2 P15735 2/20 0.60
AKT1 P31749 2/20 0.60
AKT2 P31751 2/20 0.60
MATK P42679 2/20 0.60
MAPKAPK2 P49137 2/20 0.60
BLK P51451 2/20 0.60
IRAK1 P51617 2/20 0.60
NEK4 P51957 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29966010 0.85 PARP1 (0.66) PARP1TP53CDC7PLK4MAPK13
SCHEMBL8569594 0.80 TP53 (0.68) PARP1TP53CDC7PLK4MAPK13
SCHEMBL3083940 0.80 PARP1 (1.00) PARP1TP53CDC7PLK4MAPK13
SCHEMBL3074870 0.80 PARP1 (1.00) PARP1TP53CDC7PLK4MAPK13
SCHEMBL29223232 0.79 PARP1 (0.45) PARP1TP53CDC7PLK4MAPK13
SCHEMBL30928059 0.79 PARP1 (0.45) PARP1TP53CDC7PLK4MAPK13
SCHEMBL3068409 0.79 PARP1 (1.00) PARP1TP53CDC7PLK4MAPK13
SCHEMBL3073041 0.79 PARP1 (1.00) PARP1TP53CDC7PLK4MAPK13
SCHEMBL31386834 0.78 PARP1 (0.47) PARP1TP53CDC7PLK4MAPK13
SCHEMBL3072167 0.78 PARP1 (1.00) PARP1TP53CDC7PLK4MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368169-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) 2024-11-07 US disclosed
EP-4392425-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF Impact Therapeutics (Shanghai), Inc. (CN) 2024-07-03 EP disclosed
CN-118084916-A Tri-heterocyclic compounds and uses thereof 成都赜灵生物医药科技有限公司 2024-05-28 CN disclosed
WO-2023025307-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368169-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF PARP1, PARP2, PARP11 PARP1 1/4885TP53 127/4885CDC7 1364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.